Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article]

Autor:	K P, Johnson, B R, Brooks, J A, Cohen, C C, Ford, J, Goldstein, R P, Lisak, L W, Myers, H S, Panitch, J W, Rose, R B, Schiffer, T, Vollmer, L P, Weiner, J S, Wolinsky
Rok vydání:	2002
Předmět:	Disability Evaluation Multiple Sclerosis Relapsing-Remitting Adjuvants Immunologic Injections Subcutaneous Humans Glatiramer Acetate History 20th Century Peptides Long-Term Care Randomized Controlled Trials as Topic
Zdroj:	Neurology. 57(12 Suppl 5)
ISSN:	0028-3878
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::629cf51d15e3bf4252baf92fed76cfe7 https://pubmed.ncbi.nlm.nih.gov/11902595 Zobrazit plný text záznamu